---
title: "Infinity Pharmaceuticals, Inc. (INFIQ.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/INFIQ.US.md"
symbol: "INFIQ.US"
name: "Infinity Pharmaceuticals, Inc."
industry: "Biotechnology"
---

# Infinity Pharmaceuticals, Inc. (INFIQ.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.infi.com](https://www.infi.com) |

## Company Profile

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-23T04:30:16.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 346 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.88% |  |
| Net Profit YoY | 12.48% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 90.76 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.57M |  |


**Multi Score**: D

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 212.65% | A |
| Profit Margin | -1593.93% | E |
| Gross Margin | -1091.94% | E |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.88% | B |
| Net Profit YoY | 12.48% | C |
| Total Assets YoY | -65.68% | E |
| Net Assets YoY | -3279.04% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -6.27% | D |
| OCF YoY | 15.88% | B |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.06 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 276.18% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Infinity Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "212.65%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-1593.93%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-1091.94%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.88%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "12.48%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-65.68%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3279.04%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-6.27%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "15.88%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "276.18%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/INFIQ.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/INFIQ.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/INFIQ.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.